Figure S4. Western blot analysis of gp120 and Gag p24 expression on MVC-Sens, MVC-Res, MVC-Sens(V3R) and MVC-Res(V3S) viral particles. Three hundred ng Gag p24 of the different viral isolates were solubilized in lysis buffer (100 mM (NH4)2SO4, 20 mM Tris-HCl (pH 7.5), 10 % glycerol, and 1% Triton X-100) and then loaded onto Biorad CriterionTM XT 4-12% Bis-Tris Gels under reducing conditions. Virus-associated gp120 and p24 were visualized using a sheep anti-HIV-1 gp120 polyclonal antibody (AALTO Bio Reagents LTD.) and a mouse anti-HIV-1 p24 monoclonal antibody (clone 183-H12-5C) (NIH AIDS Reagent Program), respectively, and then with the appropriate HRP-conjugated secondary antibodies (VECTOR). Bands were developed by enhanced chemiluminesce...
Objectives: Resistance of HIV-1 to CCR5 antagonists can occur without coreceptor switching by mutati...
Objectives: Resistance of HIV-1 to CCR5 antagonists can occur without coreceptor switching by mutati...
International audienceMaraviroc (MVC) is an allosteric CCR5 inhibitor used against HIV-1 infection. ...
Figure S2. Effects of MVC on fusion of MVC-Sens or MVC-Res to CD4+ T-lymphocytes. BlaM-Vpr-containin...
Figure S3. Structure and dynamics of free V3 from the MVC-Sens (grey) or MVC-Res (black) isolates. (...
Figure S6. Molecular modeling of the complex between MVC-bound CCR5 and MVC-Res V3. The graphic show...
Figure S5. Molecular modeling of the complex between CCR5 and MVC-Sens V3. The graphic shows time se...
Additional file 3: Fig. S4. Spontaneous gp120 shedding from cell surface. The susceptibility of gp41...
BACKGROUND: Maraviroc (MVC) is an allosteric CCR5 inhibitor used against HIV-1 infection. While MVC-...
Background: The CCR5 antagonist maraviroc (MVC) inhibits human immunodeficiency virus type 1 (HIV-1)...
Background: The CCR5 antagonist maraviroc (MVC) inhibits human immunodeficiency virus type 1 (HIV-1)...
Additional file 1: Fig. S1. Coexpression of HERV-K GagPro reduces HIV-1 release efficiency and infec...
Maraviroc (MVC) is an allosteric inhibitor of human immunodeficiency virus type 1 (HIV-1) entry, and...
Distribution of HIV-1 R3A PTAP–YP– in monocyte-derived macrophages (MDMs) and quantitation of Gag fl...
Titration of α4β7 inhibitors for maximal inhibition of viral replication. (A) A decreasing shift in ...
Objectives: Resistance of HIV-1 to CCR5 antagonists can occur without coreceptor switching by mutati...
Objectives: Resistance of HIV-1 to CCR5 antagonists can occur without coreceptor switching by mutati...
International audienceMaraviroc (MVC) is an allosteric CCR5 inhibitor used against HIV-1 infection. ...
Figure S2. Effects of MVC on fusion of MVC-Sens or MVC-Res to CD4+ T-lymphocytes. BlaM-Vpr-containin...
Figure S3. Structure and dynamics of free V3 from the MVC-Sens (grey) or MVC-Res (black) isolates. (...
Figure S6. Molecular modeling of the complex between MVC-bound CCR5 and MVC-Res V3. The graphic show...
Figure S5. Molecular modeling of the complex between CCR5 and MVC-Sens V3. The graphic shows time se...
Additional file 3: Fig. S4. Spontaneous gp120 shedding from cell surface. The susceptibility of gp41...
BACKGROUND: Maraviroc (MVC) is an allosteric CCR5 inhibitor used against HIV-1 infection. While MVC-...
Background: The CCR5 antagonist maraviroc (MVC) inhibits human immunodeficiency virus type 1 (HIV-1)...
Background: The CCR5 antagonist maraviroc (MVC) inhibits human immunodeficiency virus type 1 (HIV-1)...
Additional file 1: Fig. S1. Coexpression of HERV-K GagPro reduces HIV-1 release efficiency and infec...
Maraviroc (MVC) is an allosteric inhibitor of human immunodeficiency virus type 1 (HIV-1) entry, and...
Distribution of HIV-1 R3A PTAP–YP– in monocyte-derived macrophages (MDMs) and quantitation of Gag fl...
Titration of α4β7 inhibitors for maximal inhibition of viral replication. (A) A decreasing shift in ...
Objectives: Resistance of HIV-1 to CCR5 antagonists can occur without coreceptor switching by mutati...
Objectives: Resistance of HIV-1 to CCR5 antagonists can occur without coreceptor switching by mutati...
International audienceMaraviroc (MVC) is an allosteric CCR5 inhibitor used against HIV-1 infection. ...